{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:123631",
      "entity_text" : "gefitinib",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P00533",
      "entity_text" : "EGFR",
      "features" : [ {
        "to_base" : "A",
        "site" : 0,
        "feature_type" : "mutation",
        "evidence" : "mutations"
      } ],
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Earlier studies showed that the EGFR is frequently overexpressed in non-small-cell lung cancer (NSCLC) and EGFR mutations at specific amino acid residues in the kinase domain induce altered responsiveness to gefitinib, a small molecule EGFR tyrosine kinase inhibitor.",
  "reading_complete" : "2020-08-03T16:19:54Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:16:02Z",
  "trigger" : "induce",
  "evidence" : [ "EGFR mutations at specific amino acid residues in the kinase domain induce altered responsiveness to gefitinib" ],
  "pmc_id" : "3224393",
  "score" : 0
}